Jun 17 |
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
|
Jun 5 |
Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package?
|
May 10 |
iTeos Therapeutics signs agreement for $120M registered direct offering
|
May 10 |
iTeos Therapeutics reports Q1 results
|
May 10 |
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
|
May 10 |
iTeos Therapeutics Announces $120 Million Registered Direct Offering
|
May 10 |
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
|
Apr 7 |
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
|